BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24951466)

  • 1. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
    Thanasopoulou A; Tzankov A; Schwaller J
    Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
    Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Miyajima T; Onozawa M; Yoshida S; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Goto H; Sugita J; Fujisawa S; Hidaka D; Ogasawara R; Mori A; Matsuoka S; Shigematsu A; Wakasa K; Kasahara I; Saga T; Hashiguchi J; Takeda Y; Ibata M; Yutaka T; Fujimoto K; Kondo T; Teshima T
    Eur J Haematol; 2023 Oct; 111(4):620-627. PubMed ID: 37465857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to
    Porter SN; Cluster AS; Yang W; Busken KA; Patel RM; Ryoo J; Magee JA
    Elife; 2016 Nov; 5():. PubMed ID: 27879203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.
    Wang GG; Cai L; Pasillas MP; Kamps MP
    Nat Cell Biol; 2007 Jul; 9(7):804-12. PubMed ID: 17589499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
    Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
    Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia.
    Shiba N; Ichikawa H; Taki T; Park MJ; Jo A; Mitani S; Kobayashi T; Shimada A; Sotomatsu M; Arakawa H; Adachi S; Tawa A; Horibe K; Tsuchida M; Hanada R; Tsukimoto I; Hayashi Y
    Genes Chromosomes Cancer; 2013 Jul; 52(7):683-93. PubMed ID: 23630019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
    Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
    Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
    Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
    Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
    Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concealed dagger in FLT3/ITD+ AML.
    Ofran Y
    Blood; 2014 Oct; 124(15):2317-9. PubMed ID: 25301331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia.
    Palmqvist L; Argiropoulos B; Pineault N; Abramovich C; Sly LM; Krystal G; Wan A; Humphries RK
    Blood; 2006 Aug; 108(3):1030-6. PubMed ID: 16861351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
    Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
    Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
    Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
    Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.